ILLUMINA CAMBRIDGE LIMITED
Formerly known as Solexa Limited, the company serves as the UK biotechnology research and experimental development subsidiary of the US-headquartered genomics group Illumina, Inc.
Get an alert when ILLUMINA CAMBRIDGE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£84m
USD 113,200,000
highest in 3 filed years
Net assets
£686m
USD 922,735,000
Equity attributable
Employees
744
Average over period
Profit before tax
£659m
USD 886,685,000
Period ending 2025-12-28
Watch the reel
Our short-form breakdown of ILLUMINA CAMBRIDGE LIMITED's latest filing
Illumina Cambridge pulls in £3.2bn a year as the UK arm of the US genomics giant. But a massive finance income boost meant pre-tax profits — and the boardroom payout — stole the show. 🧬📊
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-28
| Metric | Trend | 2023-12-31 | 2024-12-29 | 2025-12-28 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £2,408,754,366 | £2,372,236,343 | £2,413,820,884 | — | |
| Operating profit | £152,053,512 | £82,341,137 | £110,657,005 | — | |
| Profit before tax | £416,695,652 | £377,104,422 | £659,000,372 | — | |
| Net profit | £383,816,425 | £312,634,708 | £621,623,188 | — | |
| Cash | £41,945,745 | £49,941,286 | £84,132,293 | — | |
| Total assets less current liabilities | £762,382,014 | £700,596,061 | £730,479,376 | — | |
| Net assets | £732,798,216 | £630,463,025 | £685,793,385 | — | |
| Equity | £732,798,216 | £630,463,025 | £685,793,385 | — | |
| Average employees | 823 | 731 | 744 | — | |
| Wages | £72,772,947 | £69,891,490 | £70,187,291 | — | |
| Directors' remuneration | £978,818 | £642,884 | £1,332,590 | — |
Figures converted to GBP from USD at 0.743 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing covers about 12 months versus 12 months prior. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-29 | 2025-12-28 |
|---|---|---|---|---|
| Operating margin | 6.3% | 3.5% | 4.6% | |
| Net margin | 15.9% | 13.2% | 25.8% | |
| Return on capital employed | 19.9% | 11.8% | 15.1% | |
| Gearing (liabilities / total assets) | 25.1% | 38.0% | 28.2% | |
| Current ratio | 3.10x | 2.33x | 3.14x | |
| Interest cover | 15.39x | — | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- ILLUMINA CAMBRIDGE LIMITED 2008-01-04 → present
- SOLEXA LIMITED 1998-10-09 → 2008-01-04
- INTERCEDE 1356 LIMITED 1998-09-02 → 1998-10-09
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have prepared an assessment of the going concern status of the Company based on resources available to the Company, including both cash and tangible assets, and have concluded that these resources will be sufficient to sustain the Company's activities for the period to 31 December 2027, being the going concern assessment period.”
Group structure
- ILLUMINA CAMBRIDGE LIMITED · parent
- Illumina Singapore Pte. Ltd 100%
- Illumina Canada ULC 100%
- BlueBee Holding B.V. 100%
- Emedgene Technologies Ltd 100%
- Illumina Colombia S.A.S. 100%
- Illumina Mexico Productos de Biotecnologia 99%
Significant events
- “During the period, the directors approved the payment of dividends totalling $730 million (2024: $580 million).”
- “On 30 January 2026, the Company purchased intellectual property and other assets from Pacific Biosciences.”
- “On 6 February 2026, the Company issued an intercompany loan of $10M to Illumina International Genomics Pte Ltd, followed by a further $6.5M on 30 March 2026. The loan was fully repaid on 26 May 2026.”
- “On 19 February 2026, the Company received a dividend of $60,000,000 from Illumina Singapore Pte. Ltd.”
- “On 8 April 2026, the Company made a capital contribution of $9,174,397 to Bluebee Holding B.V.”
- “On 22 April 2026, the Company received a dividend of $26,000,000 from Illumina Singapore Pte. Ltd.”
- “On 23 June 2026, Illumina Singapore Pte. Ltd approved a dividend to be paid to the Company of $50,000,000.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 36 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ROBINSON, Mark James | Director | 2019-11-04 | Dec 1975 | British |
| SALES, Nicholas Simon | Director | 2025-05-15 | Mar 1975 | British |
Show 36 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ABELL, James Foster | Secretary | 1998-10-12 | 2001-11-20 |
| CABOU, Christian | Secretary | 2007-01-26 | 2013-04-22 |
| DADSWELL, Charles | Secretary | 2013-04-22 | 2024-11-22 |
| DOOGAN, Andrew Kevin | Secretary | 2024-11-22 | 2025-03-07 |
| PALMER, Leigh Graham | Secretary | 2001-11-20 | 2007-01-26 |
| MITRE SECRETARIES LIMITED | Corporate Nominee Secretary | 1998-09-02 | 1998-10-12 |
| ALLEN, Stephen David | Director | 2004-01-27 | 2007-01-26 |
| BALASUBRAMANIAN, Shankar, Dr | Director | 1998-10-12 | 2007-01-26 |
| BERRIMAN, John Edward | Director | 1998-10-12 | 2004-06-08 |
| CARTHY, Mark | Director | 2001-09-20 | 2005-04-19 |
| COMPTON, Richard Alan | Director | 2015-04-29 | 2016-05-03 |
| CRANFIELD, Nicola Letha, Ms. | Director | 2021-12-03 | 2025-05-15 |
| DANIEL, Tom James | Director | 2001-09-20 | 2005-04-19 |
| DESOUZA, Francis | Director | 2015-04-29 | 2017-04-13 |
| DOWDY, Paula Lynn | Director | 2016-10-24 | 2021-07-23 |
| EDWARDS, Rebecca Jane | Director | 2018-10-08 | 2021-11-19 |
| ELETR, Sam, Dr | Director | 2002-01-29 | 2004-07-30 |
| FLATLEY, Jay | Director | 2007-01-26 | 2015-04-29 |
| HAUSER, Hermann Maria | Director | 2004-07-30 | 2005-04-19 |
| HENRY, Christian Ogren | Director | 2007-12-20 | 2017-04-13 |
| JENNINGS, Richard Charles, Dr | Director | 1998-10-12 | 2001-09-20 |
| KLENERMAN, David | Director | 1998-10-12 | 2001-09-20 |
| LLOYD HARRIS, Quentin Lionel Genghis, Dr | Director | 2004-06-08 | 2005-04-19 |
| MCCOOKE, Nicholas John | Director | 2001-01-24 | 2004-08-09 |
| MCGRATH, Ronald James | Director | 2017-04-13 | 2018-01-22 |
| NEL, Andre Jacques | Director | 2015-04-29 | 2019-11-04 |
| ORPIN, Timothy Sean | Director | 2013-03-14 | 2015-04-29 |
| REEVES, Barbara | Nominee Director | 1998-09-02 | 1998-10-12 |
| RICH, Michael William | Nominee Director | 1998-09-02 | 1998-10-12 |
| RINK, Timothy James, Dr | Director | 2000-07-19 | 2007-01-26 |
| SMITH, Anthony John | Director | 2002-01-29 | 2007-01-26 |
| STAPLEY, Marc Andrew | Director | 2012-05-08 | 2015-04-29 |
| VAN OENE, Mark David | Director | 2017-09-14 | 2018-10-08 |
| VERHOEF, Bastiaan Abram Willem | Director | 2023-04-28 | 2024-02-07 |
| WEST, John Stephen | Director | 2004-08-06 | 2007-01-26 |
| WILLIAMSON, Alan Rowe, Dr | Director | 2000-07-19 | 2004-07-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Illumina Inc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors (as firm), Significant influence (as firm) | 2016-04-06 | Active |
Filing timeline
Last 20 of 189 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-26 | AA | accounts | Accounts with accounts type full | |
| 2025-09-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-18 | AA | accounts | Accounts with accounts type full | |
| 2025-05-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-16 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-13 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-11-28 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-11-28 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-09-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-31 | AA | accounts | Accounts with accounts type full | |
| 2024-02-07 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-28 | AA | accounts | Accounts with accounts type full | |
| 2023-09-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-05-05 | AP01 | officers | Appoint person director company with name date | |
| 2022-09-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-30 | AA | accounts | Accounts with accounts type full | |
| 2021-12-03 | AP01 | officers | Appoint person director company with name date | |
| 2021-12-01 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-14 | AA | accounts | Accounts with accounts type full | |
| 2021-09-02 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.